TREATMENT OF HBV AND HDV CO-INFECTION USING LAMIVUDINE
Abstract
Objective: To see effect of Lamivudine on sero conversion of HBeAg positive cases co infectedwith Delta hepatitis. Methods: Hepatitis B positive patients with deranged liver functions for 6months were tested for HBeAg, HBV DNA and anti-Delta virus (HDV), using ELISA. Patientswere divided into 2 groups, group 1: HBeAg, HBV DNA positive (wild type) but delta negativeand group 2: HBeAg, HBV DNA positive (wild type) with delta positive. Lamivudine (100 mg)was advised to both groups till sero-conversion. Results: Of 124 cases in year 1999–2005, 69were in (Group 1), and 55 were in (Group 2). Eighty percent were males in both groups. ALTnormalisation occurred in 75%, 24% cases within 6 months respectively. At the start of therapymean HBeAg was 289±189 in group 1 and 142±160 in group 2. With treatment, the values did notchange much till 12 months of therapy. The fall was significantly slow in delta positive cases. At36 months 26 (38%) cases in group 1 and 9 (16.4%) cases in group 2 sero-converted. Nine casesin each group remained non-responders while 2 in each group relapsed. Conclusion: Wild type ofHBV/HDV co-infected cases have a 16% chance of seroconversion which negates the concept thatonce infected with delta virus there is not much that can be done.Keywords: Hepatitis B virus, Delta hepatitis, co-infection, sero-conversion, fulminant hepatitis,lamuvidine, interferon, entecavirReferences
REFERENCES
Andre F. Hepatitis B epidemiology in Asia: the Middle East
and Africa Vaccine 2000;18 (Suppl 1):s20–2.
Mumtaz K, Hamid SS, Adil S, Afaq A, Islam M, Abid S, et al.
Epidemiology and clinical pattern of hepatitis Delta virus
infection in Pakistan. J Gastroenterol Hepatol 2005;20:1503–7.
Zuberi SJ. International Hepatology Communication 5
;19–26.
Lau DT, Doo E, Park Y, Kleiner DF, Schmid P, Mary C.
Kuhns MC, et al. Lamuvidine for chronic Delta
hepatitis.Hepatology 1999;30(2):579–81.
Dienstag JL, Perrillo RP, Schiff ER, Bartholomew M, Vicary C,
Rubin M. A preliminary trial of lamivudine for chronic
hepatitis B infection. N Engl J Med 1995;333:1657–61.
Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann H-WL,
Goodman Z, et al. US Lamivudine Investigator Group.
Lamivudine as initial treatment for chronic hepatitis B in the
United States. New England. J Med 1999;341:1256–63.
Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt
C, et al. Prevalence and clinical correlates of YMDD variants
during lamivudine therapy for patients with chronic hepatitis B.
Clin Infect Dis 2003;36:687–96.
Guan R, Lai CL, Liaw YF, Lim SG, Lee CM. Efficacy and
safety of 5-years Lamivudine treatment of Chinese patients
with chronic hepatitis B. J Gastroenterol Hepatol
;16(suppl 1):A60.
Lai C-L, Dienstag J, Schiff E, Leung NWY, Atkins M, Hunt C,
et al. Prevalence and clinical correlates of YMDD variants
during lamivudine therapy of patients with chronic B. Clin
Infect Dis 2003;36:687–96.
Locarnini S. Hepatitis B viral resistance: mechanisms and
diagnosis. J Hepatol 2003;39:S124–S132.
Four year data on Entecavir Resistance in Nucleoside–naïve
patients with chronic hepatitis B. 42nd EASL Conference April
–15, 2007, Barcelona, Spain.
Leung N, Sherman M, Peng CY, Entecavir (ETV) Results in
Higher HBV- DNA Reduction vs Adefovir (ADV) in
Chronically Infected HBeAg+ Antiviral-Naive Adults: 48-Week
Results (EARLY Study). Digestive Disease Week 2007 (DDW
. Washington, DC. May 19–24, 2007. Abstract S-1773.
H, Arif A, Ahmed W, Alam E. YMDD Mutation in Pakistani
Patients. The comparison of Eastern Response with the
Western Response (unpublished data) presented in PSG
Congress 2006 Karachi.
Wong DK, Cheung AM, O’Rourke K, Naylor CD, Detsky AS,
Heathcote J. Effect of alpha-treatment in patients with hepatitis
B e antigen-positive chronic hepatitis B. A meta-analysis. Ann
Intern Med 1993;119:312–23.
Krossgaard K, Bindslev N, Christensen E, Craxi A, Schlichting
P, Schalm S, et al. The treatment effect of alpha interferon in
chronic hepatitis B is independent of pre-treatment variables.
Results based on indivigual patient data from 10 clinical
controlled trials. European Concerted Action on Viral Hepatitis
(Eurohep). J Hepatol 1994;21:646–55.
Published
Issue
Section
License
Journal of Ayub Medical College, Abbottabad is an OPEN ACCESS JOURNAL which means that all content is FREELY available without charge to all users whether registered with the journal or not. The work published by J Ayub Med Coll Abbottabad is licensed and distributed under the creative commons License CC BY ND Attribution-NoDerivs. Material printed in this journal is OPEN to access, and are FREE for use in academic and research work with proper citation. J Ayub Med Coll Abbottabad accepts only original material for publication with the understanding that except for abstracts, no part of the data has been published or will be submitted for publication elsewhere before appearing in J Ayub Med Coll Abbottabad. The Editorial Board of J Ayub Med Coll Abbottabad makes every effort to ensure the accuracy and authenticity of material printed in J Ayub Med Coll Abbottabad. However, conclusions and statements expressed are views of the authors and do not reflect the opinion/policy of J Ayub Med Coll Abbottabad or the Editorial Board.
USERS are allowed to read, download, copy, distribute, print, search, or link to the full texts of the articles, or use them for any other lawful purpose, without asking prior permission from the publisher or the author. This is in accordance with the BOAI definition of open access.
AUTHORS retain the rights of free downloading/unlimited e-print of full text and sharing/disseminating the article without any restriction, by any means including twitter, scholarly collaboration networks such as ResearchGate, Academia.eu, and social media sites such as Twitter, LinkedIn, Google Scholar and any other professional or academic networking site.
